Document is current
Any future updates will be listed below
-
Authors
Meyerhoff, Robert R
Chen, Alan C
Anadon-Galindo, Carmen
Kemeny, Gabor
Lyniv, Liliana
Jain, Vaibhav
Evangelous, Tyler
Berry, Madison
Steadman, Katelyn
Abramson, Karen
Wiehe, Kevin
Weinhold, Kent
Gregory, Simon
Conjeo-Garcia, Jose
Williams, Wilton B
Antonia, Scott J
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02818920 at ClinicalTrials.govnct02818920 at ClinicalTrials.govDocuments that mention this clinical trial
Perioperative pembrolizumab in early-stage non-small cell lung cancer (NSCLC): safety, efficacy, and exploratory biomarker analysis
https://doi.org/10.1136/jitc-2024-010395
Perioperative pembrolizumab in early-stage non-small cell lung cancer (NSCLC): conventional and distribution-based immune profiling of the tumor microenvironment and peripheral circulation
https://doi.org/10.1136/jitc-2025-012432
863 Characterization of tumor-infiltrating plasma cells in patients with NSCLC treated with neoadjuvant pembrolizumab
https://doi.org/10.1136/jitc-2024-sitc2024.0863
Documents that mention this clinical trial
Perioperative pembrolizumab in early-stage non-small cell lung cancer (NSCLC): safety, efficacy, and exploratory biomarker analysis
https://doi.org/10.1136/jitc-2024-010395
Perioperative pembrolizumab in early-stage non-small cell lung cancer (NSCLC): conventional and distribution-based immune profiling of the tumor microenvironment and peripheral circulation
https://doi.org/10.1136/jitc-2025-012432
863 Characterization of tumor-infiltrating plasma cells in patients with NSCLC treated with neoadjuvant pembrolizumab
https://doi.org/10.1136/jitc-2024-sitc2024.0863
- License Information
